Drug Profile
Pinatuzumab vedotin - Genentech
Alternative Names: ACD22-VCMMAE; Anti-CD22-ADC; Anti-CD22-MCC-DM1; DCDT 2980S ADC; DCDT 2980S antibody-drug conjugate; DCDT-2980S; FCU-2703; RG-7593; RO-5541072; RO-5541072-000Latest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator Genentech
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 08 Oct 2020 Seattle Genetics is now called Seagen
- 07 Feb 2019 Genentech completes the phase II ROMULUS trial in Diffuse large B cell lymphoma and Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA, Canada, France, Germany, Italy and the Netherlands (NCT01691898)